Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Helsinn Group has signed an entered into an agreement with DARA BioSciences for US commercial rights of Gelclair, indicated for the treatment of oral mucositis.
Subscribe to our email newsletter
DARA plans to launch Gelclair, a topical gel used to coat and protect the oral cavity to reduce pain, in the first quarter of 2013.
DARA chief executive officer David Drutz said the exclusive agreement with Helsinn for rights to commercialize Gelclair is a significant milestone that provides us with an important commercial product in an area of significant medical need.
"Helsinn offers DARA a respected partner with extensive experience in the oncology supportive care market," Drutz added.
Helsinn CEO Riccardo Braglia said, "We believe DARA will support Gelclair with the programs necessary to ensure health care providers and patients have this valuable product available as part of their treatment regimen."